公开(公告)号：US20230052629A1

公开(公告)日：2023-02-16

申请号：US17352734

申请日：2021-06-21

Applicant: Novartis AG

Inventor： Christopher Becker ,  Xiaolin Li ,  Peichao Lu ,  Naomi Samadara Rajapaksa ,  David Charles Tully ,  Xiaojing Michael Wang ,  Qian Zhao

IPC: C07D471/04 ,  A61P31/22

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

公开(公告)号：US10351576B2

公开(公告)日：2019-07-16

申请号：US15569498

申请日：2016-04-29

Applicant: NOVARTIS AG

Inventor： Donatella Chianelli ,  Xiaodong Liu ,  Valentina Molteni ,  John Nelson ,  Jason Roland ,  Paul Vincent Rucker ,  David Charles Tully

IPC: C07D491/052 ,  C07D493/04 ,  A61K31/4162 ,  A61K31/427 ,  A61K31/5377 ,  A61K31/635

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

公开(公告)号：US11072610B2

公开(公告)日：2021-07-27

申请号：US16569107

申请日：2019-09-12

Applicant: Novartis AG

Inventor： Christopher Becker ,  Xiaolin Li ,  Peichao Lu ,  Naomi Samadara Rajapaksa ,  David Charles Tully ,  Xiaojing Michael Wang ,  Qian Zhao

IPC: C07D471/04 ,  A61P31/22

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

公开(公告)号：US10077240B2

公开(公告)日：2018-09-18

申请号：US15598734

申请日：2017-05-18

Applicant: NOVARTIS AG

Inventor： Donatella Chianelli ,  Valentina Molteni ,  John Nelson ,  Jason Thomas Roland ,  Paul Vincent Rucker ,  David Charles Tully

IPC: C07D231/54 ,  A61K31/4745 ,  C07D471/06 ,  A61K31/4162 ,  A61K31/416 ,  C07D491/052 ,  C07D471/04 ,  A61K31/4439

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

公开(公告)号：US20230365511A1

公开(公告)日：2023-11-16

申请号：US18164974

申请日：2023-02-06

Applicant: Novartis AG ,  Gilead Sciences, Inc.

Inventor： Zef Konst ,  Yipin Lu ,  Robert Joseph Moreau ,  Naomi Samadara Rajapaksa ,  Galen Shearn-Nance ,  David Charles Tully ,  Michael Robert Turner ,  Joseph Michael Young ,  Qian Zhao ,  Britton K. Corkey ,  Samuel E. Metobo

IPC: C07D243/10

CPC classification number: C07D243/10

Abstract: The invention provides compounds of Formula (I)





as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

公开(公告)号：US11667613B2

公开(公告)日：2023-06-06

申请号：US17030540

申请日：2020-09-24

Applicant: Novartis AG ,  Gilead Sciences, Inc.

Inventor： Zef Konst ,  Yipin Lu ,  Robert Joseph Moreau ,  Naomi Samadara Rajapaksa ,  Galen Shearn-Nance ,  David Charles Tully ,  Michael Robert Turner ,  Joseph Michael Young ,  Qian Zhao ,  Britton K. Corkey ,  Samuel E. Metobo

IPC: C07D471/04 ,  C07D471/14 ,  A61K31/4162 ,  A61K31/437 ,  A61P31/22 ,  C07D243/10

CPC classification number: C07D243/10

Abstract: The invention provides compounds of Formula (I)




as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

公开(公告)号：US11021446B2

公开(公告)日：2021-06-01

申请号：US16854762

申请日：2020-04-21

Applicant: NOVARTIS AG

Inventor： Donatella Chianelli ,  Runyan Li ,  Valentina Molteni ,  John Nelson ,  Jason Thomas Roland ,  Paul Vincent Rucker ,  David Charles Tully ,  Xiaoyang Wang ,  Liladhar Murlidhar Waykole ,  Yubo Zhang ,  Bo Zhou

IPC: C07D231/54 ,  C07D471/04 ,  C07D491/052 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/4439 ,  A61K31/4745 ,  C07D471/06

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

公开(公告)号：US10683271B2

公开(公告)日：2020-06-16

申请号：US16056881

申请日：2018-08-07

Applicant: NOVARTIS AG

Inventor： Donatella Chianelli ,  Xiaodong Liu ,  Valentina Molteni ,  John Nelson ,  Jason Thomas Roland ,  Paul Vincent Rucker ,  David Charles Tully

IPC: C07D231/54 ,  A61K31/4745 ,  A61K31/4439 ,  A61K31/4162 ,  C07D471/04 ,  C07D471/06 ,  C07D491/052 ,  A61K31/416

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

公开(公告)号：US20200079772A1

公开(公告)日：2020-03-12

申请号：US16569107

申请日：2019-09-12

Applicant: Novartis AG

Inventor： Christopher Becker ,  Xiaolin Li ,  Peichao Lu ,  Naomi Samadara Rajapaksa ,  David Charles Tully ,  Xiaojing Michael Wang ,  Qian Zhao

IPC: C07D471/04 ,  A61P31/22

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

公开(公告)号：US20190062283A1

公开(公告)日：2019-02-28

申请号：US16056881

申请日：2018-08-07

Applicant: NOVARTIS AG

Inventor： Donatella CHIANELLI ,  Runyan LI ,  Valentina Molteni ,  John Nelson ,  Jason Thomas Roland ,  Paul Vincent Rucker ,  David Charles Tully ,  Xiaoyang WANG ,  Liladhar Murlidhar WAYKOLE ,  Yubo ZHANG ,  Bo ZHOU

IPC: C07D231/54 ,  A61K31/4745 ,  A61K31/4439 ,  A61K31/4162 ,  C07D471/04 ,  C07D471/06 ,  C07D491/052 ,  A61K31/416

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).